COMMUNIQUÉS West-GlobeNewswire

Curia publie son rapport ESG (environnement, social et gouvernance) 2024
29/10/2025
ALBANY, New York, 29 oct. 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), l’une des principales organisations de recherche, de développement et de fabrication sous contrat, a annoncé aujourd’hui la publication de [...]
CORRECTION – Solana Company Announces Updated SOL Holdings and Industry Leading Staking Yield
29/10/2025
NEWTOWN, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Wednesday, October 29th by Solana Company (NASDAQ: HSDT), please note that in the first sentence of the third paragraph, the [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
29/10/2025
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 29 octobre 2025 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
29/10/2025
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 29 octobre 2025 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui [...]
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
29/10/2025
WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), in ongoing community, industry, and academic engagements, has continued to underscore its biopharma [...]
EmblemHealth and Prime Therapeutics Pioneer New Pharmacy Benefit Collaboration
29/10/2025
Unique partnership, in collaboration with Amazon Pharmacy and Judi Health, brings transparent pricing, digital convenience, and fast, free home delivery of prescription medications for members NEW YORK, Oct. 29, 2025 ( [...]
RAMSAY SANTE : communiqué de mise à disposition du document d'enregistrement universel 2025
29/10/2025
COMMUNIQUÉ DE PRESSE Paris, le 29 octobre 2025 COMMUNIQUÉ DE MISE À DISPOSITION DU DOCUMENT D’ENREGISTREMENT UNIVERSEL 2025 Le Document d’enregistrement universel 2025 de Ramsay Générale de Santé a été déposé auprès de [...]
RAMSAY SANTE : availability of the Universal Registration Document 2025
29/10/2025
PRESS RELEASE Paris, 29 th October 2025 AVAILABILITY OF THE UNIVERSAL REGISTRATION DOCUMENT 2025 Ramsay Générale de Santé's 2025 Universal Registration Document was filed with the Autorité des marchés financiers (AMF) [...]
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
29/10/2025
SAN FRANCISCO and BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous [...]
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
29/10/2025
New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy, including JAKs [...]
Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug
29/10/2025
Data from the dose optimization trial expected soon ProLectin-M is positioned as the first oral antiviral sugar chemistry drug BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the [...]
Betterguards Launches The BetterGuard Lite, a Powerful New Ankle Protection System with Breakthrough Design
29/10/2025
The BetterGuard Lite features an impossibly thin, lightweight design at an affordable price for athletes worldwide NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Betterguards , a sports technology innovator, today [...]
FDA Grants Orphan Drug Designation to Dewpoint Therapeutics’ DPTX3186 for the Treatment of Gastric Cancer
29/10/2025
First orphan designation ever granted to a condensate-modulating therapeutic Builds on recent IND opening for DPTX3186, a first-in-class oral condensate modulator targeting the Wnt/ β -catenin pathway Provides key [...]
OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category
29/10/2025
Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 [...]
MEDIROM to Launch New Treasury Strategy Utilizing Cryptocurrency
29/10/2025
Aimed at incentivize large-scale vital data collection TOKYO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc., (Headquarters: Minato-ku, Tokyo; President and CEO: Kouji Eguchi; listed on the [...]
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
29/10/2025
NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit 1 Data showed consistent improvements across secondary outcome measures, and a favorable safety [...]
Plum Tree Launches New Chronic Illness Therapy Program
29/10/2025
ST. CHARLES, Ill., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Plum Tree Psychology, Ltd., a leading child and family mental health practice in the Fox Valley, today announced the launch of Hoot & Holler, a new Chronic [...]
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
29/10/2025
VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activity Final ADAPT SC+ results show ~60% of VYVGART [...]
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
29/10/2025
Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activities of Daily Living [...]

Pages